{"url_path":"/sec/crdf/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-344645-index.html","accession_number":"0001193125-26-344645","cik":"0001213037","ticker":"CRDF","issuer_name":"Cardiff Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-344645-index.html","primary_entity_key":"0001213037","primary_entity_name":"Cardiff Oncology, Inc."},"word_count":66,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n99.1\n\n[Press Release of Cardiff Oncology, Inc. dated August 11, 2026](crdf-ex99_1.htm)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCARDIFF ONCOLOGY, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nAugust 11, 2026\n\nBy:\n\n/s/ Mani Mohindru\n\n \n\n \n\n \n\nMani Mohindru\n\nChief Executive Officer"}